25 — 6 (44) 2022 — Khamroev E.E., Nurboev F.E., Pulatova Sh.Kh., POLYMORBIDITY AND ITS RELATION TO THE UNFAVORABLE COURSE OF CHRONIC HEART FAILURE IN ELDERLY PATIENTS

POLYMORBIDITY AND ITS RELATION TO THE UNFAVORABLE COURSE OF CHRONIC HEART FAILURE IN ELDERLY PATIENTS

Khamroev E.E., Republican Scientific Center for Emergency Medical Assistance Bukhara branch Bukhara State Medical Institute

Nurboev F.E., Republican Scientific Center for Emergency Medical Assistance Bukhara branch Bukhara State Medical Institute

Pulatova Sh.Kh., Republican Scientific Center for Emergency Medical Assistance Bukhara branch Bukhara State Medical Institute

Resume

This study was carried out to evaluate polymorbidity taking into account geriatric syndromes and their relationship with the course of chronic heart failure (CHF) in outpatients aged 60 years and older. We conducted an open, prospective, non-randomized study. The main group included 80 patients with CHF, the comparison group – 40 patients without CHF. Conducted clinical examination, ECG, echocardiography, two-photon X-ray absorptiometry. The scale of assessment of clinical status in CHF,Charlson comorbidity index were used. The criteria for frailty were the presence of at least 3 signs due FRAIL scale. Mean follow-up was 24.1±13.0 months. All patients with CHF (100%) and 92.5% of the comparison group had a concomitant pathology. A combination of 3 or more of any diseases was more common in CHF compared to control group (p=0.008), CKD (66%) and obesity (35%) were the most common pathology. Combinations of osteoporosis and CKD (28%), obesity and CKD (23%) were the most frequent in the CHF patients, a combination of obesity and CKD (28%), obesity and diabetes (18%) – without CHF patients. The same incidence of osteoporosis (p=0.768), falls (p=0.980), fractures (p=0.549) and frailty (p=0.828) was observed in CHF patients and different EFLV, but prevalence of frailty was observed at the age of 75 years and older. During the observation period, 24% CHF patients and 5% patients without CHF (p=0.022) died. The worst survival of patients with ischemic genesis of CHF and osteoporosis was noted. The factors associated with an increased risk of death in CHF patients were the ischemic etiology of CHF (OR 8.33; 95% CI 1.11–62.4; p=0.039), male gender (OR 7.91; 95% CI 2.3–27.2; p=0.001), LV EF

Key words: CHF, polymorbidity, CHF etiology, survival of patients with CHF, age-related changes

First page

148

Last page

153

For citation: Khamroev E.E., Nurboev F.E., Pulatova Sh.Kh., POLYMORBIDITY AND ITS RELATION TO THE UNFAVORABLE COURSE OF CHRONIC HEART FAILURE IN ELDERLY PATIENTS //New Day in Medicine 6(44)2022 148-153 https://clck.bar/L063f0

LIST OF REFERENCES:

1. Кенжаев, М. Л., & Ризаева, М. Ж. (2020). Клиническое течение фибрилляции предсердий у больных ишемической болезнью сердца. //In Наука и инновации-современные концепции (p. 103-109).
2. Rizaeva, M. Z. (2022). The clinical course of atrial fibrillation in patients with coronary heart disease. //European journal of molecular medicine, 2(1).
3. Пулатова, Ш. Х. (2019). Особенности тромболитической терапии у больных острым инфарктом миокарда. //Вестник экстренной медицины, 12(6).
4. Mamas M.A., Sperrin M., Watson M.C., Coutts A., Wilde K., Burton C. et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland: Outcomes in heart failure and cancer. European Journal of Heart Failure. 2017;19(9):1095–104. DOI: 10.1002/ejhf.822
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. //Journal of Chronic Diseases. 1987;40(5):373–83. DOI: 10.1016/0021-9681(87)90171-8
6. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. [Internet] Available at: http://www.who.int/vmnis/indicators/haemoglobin/en/
7. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. //European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/ eurheartj/ehw128
8. Nedogoda S.V., Barykina I.N., Salasyuk A.S. National clinical guidelines for obesity: concept and perspectives. //Journal of Volgograd State Medical University. 2017;1(61):134–40. [Russian: Недогода С.В., Барыкина И.Н., Саласюк А.С. Национальные клинические рекомендации по ожирению: концепция и перспективы. Вестник Волгоградского государственного медицинского университета. 2017;1(61):134–40]
9. Belenkov Yu.N., Mareev V.Yu. Principles of rational treatment of chronic heart failure. -M.: Media Medika;2000. – 266 p. [Russian: Беленков Ю.Н., Мареев В.Ю. Принципы рационального лечения хронической сердечной недостаточности. – М.: Медиа Медика; 2000. – 266с]
10. Максимов М. Л. и др. Общие вопросы клинической фармакологии и фармакотерапии. – 2020.
11.   Мусаева, Д.М., Клычова, Ф.К., Насырова, С.З., Аслонова, М.Ж., Очилова, Г.С., Максимов, М.Л. 2019. Антибиотики.
12.   Мусаева Д. М., Очилов А. К. Особенности гена CYP2C19 для индивидуализиции фармакотерапии //Фармакология разных стран. – 2020. – С. 114-116.
13.   Oblokulov A. R., Musaeva D. M., Elmuradova A. A. Clinical and epidemiological characteristics of the new coronavirus infection (COVID-19) //New day in medicine. – 2020. – №. 2. – С. 30.
14. Van Deursen V.M., Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey: Comorbidities in heart failure. European Journal of Heart Failure. 2014;16 (1):103– 11. DOI: 10.1002/ejhf.30.